# First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Source: https://onco.cc/trials/nct06877650/  
OnCo record `nct06877650` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab and Ivonescimab in advanced solid tumours, run by Shanghai JMT-Bio Inc., now recruiting.

## Summary

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06877650 by Shanghai JMT-Bio Inc., with 436 participants planned, started 2025-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: JMT108, Pembrolizumab and Ivonescimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06877650
- Phase: 1/2
- Setting: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.
- Sponsor: Shanghai JMT-Bio Inc.
- Enrolled: 436

## Sources

- ClinicalTrials.gov NCT06877650: https://clinicaltrials.gov/study/NCT06877650

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct06877650.json